我国生物制药行业经营的绩效评价

发布时间：2018-02-02 14:33

本文关键词： 生物制药行业经营绩效 BCC模型 Malmquist生产率指数　出处：《江西师范大学》2014年硕士论文　论文类型：学位论文

【摘要】：生物制药行业在国内处于非常有利的的发展条件。首先，对生物制药行业发展政策形成有利的支持。生物制药行业易受政策影响，积极有力的政策环境能够推动行业的迅速发展。其次，医疗卫生水平帮助提高生物制药行业的健康、稳定的发展水平。随着我国国民经济的快速发展以及医疗卫生水平不断提高，越来越多的人能够消费起价格相对较高的生物药品。然而，，我国生物制药行业存在诸多问题，如研发资金投入比重不足、科研创新能力薄弱、科技成果转化率低和产能过剩竞争过度等问题。在此背景下，评价我国生物制药行业的经营绩效，有利于促进该行业稳定健康以及提升其竞争力。文章采用BCC模型以及基于DEA模型的Malmquist生产率指数的方法对我国生物制药行业经营的绩效进行评估。选取长春高新、双鹭药业等25家主营生物药品的上市公司作为样本。以证监会行业标准划分为基础，这25家上市公司包括有12家属于生物制品业，12家属于生物药品制造业，1家属于其他生物制品业。本文采用总资产、主营业务成本和各项费用作为投入指标，净利润和主营业务收入作为产出指标。在本文中，采用BCC模型对我国25家生物制药行业主要上市公司2008—2012年间的经营绩效进行评价，并结合了Malmquist生产率指数，对样本期间内生物制药行业上市公司经营绩效变换进行了动态评价。研究结果显示：第一，采用静态评价得到的结果是规模效率明显偏低，样本期间内我国生物制药行业主要上市公司的经营绩效相对不高，需要改善；第二，运用动态评价得出技术水平下降呈现变化是全要素效率下降的主要原因。最后，对本人的研究成果做了总结，以及基于实证研究得出的结论，提出相应的对策建议，以期促进生物制药行业的稳定发展。
[Abstract]:Biopharmaceutical industry in China is in a very favorable development conditions. First of all, the development of the biopharmaceutical industry policy to form a favorable support. Biopharmaceutical industry is vulnerable to the impact of the policy. An active policy environment can promote the rapid development of the industry. Secondly, the level of health care helps to improve the health of the biopharmaceutical industry. With the rapid development of our national economy and the continuous improvement of medical and health standards, more and more people can consume the relatively high prices of biological drugs. There are many problems in the biopharmaceutical industry in China, such as insufficient proportion of R & D funds, weak ability of scientific research and innovation, low conversion rate of scientific and technological achievements and excessive overcapacity competition. The evaluation of the performance of the biopharmaceutical industry in China is beneficial to promote the stability and health of the industry and enhance its competitiveness. This paper uses BCC model and Malmquist productivity index based on DEA model to evaluate the performance of Chinese biopharmaceutical industry. A sample of 25 listed companies, including Shuanglu Pharmacy, which specializes in biopharmaceuticals. Based on the industry standards of the CSRC, 12 of the 25 listed companies are in the biological products industry. In this paper, total assets, main business costs and various expenses are used as input indicators, while net profit and main business income are taken as output indicators. In this paper, the BCC model is used to evaluate the operating performance of 25 biopharmaceutical companies in China from 2008 to 2012. Combined with the Malmquist productivity index, the dynamic evaluation of the operating performance transformation of the listed companies in the biopharmaceutical industry during the sample period is carried out. The results show that: first. The result of the static evaluation is that the scale efficiency is obviously low, and the operating performance of the main listed companies in the biopharmaceutical industry in China is relatively low during the sample period, which needs to be improved. Secondly, the dynamic evaluation shows that the decline of technical level is the main reason for the decline of total factor efficiency. Finally, this paper summarizes my research results, and based on the conclusions of empirical research, puts forward corresponding countermeasures and suggestions, in order to promote the stable development of the biopharmaceutical industry.
【学位授予单位】：江西师范大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.72

【参考文献】